The clinical course of acute pancreatitis and the inflammatory mediators that drive it

Leena Kylänpää, Zoltán Rakonczay Jr, Derek A O'Reilly, Leena Kylänpää, Zoltán Rakonczay Jr, Derek A O'Reilly

Abstract

Acute pancreatitis (AP) is a common emergency condition. In the majority of cases, it presents in a mild and self-limited form. However, about 20% of patients develop severe disease with local pancreatic complications (including necrosis, abscess, or pseudocysts), systemic organ dysfunction, or both. A modern classification of AP severity has recently been proposed based on the factors that are causally associated with severity of AP. These factors are both local (peripancreatic necrosis) and systemic (organ failure). In AP, inflammation is initiated by intracellular activation of pancreatic proenzymes and/or nuclear factor-κB. Activated leukocytes infiltrate into and around the pancreas and play a central role in determining AP severity. Inflammatory reaction is first local, but may amplify leading to systemic overwhelming production of inflammatory mediators and early organ failure. Concomitantly, anti-inflammatory cytokines and specific cytokine inhibitors are produced. This anti-inflammatory reaction may overcompensate and inhibit the immune response, rendering the host at risk for systemic infection. Currently, there is no specific treatment for AP. However, there are several early supportive treatments and interventions which are beneficial. Also, increasing the understanding of the pathogenesis of systemic inflammation and the development of organ dysfunction may provide us with future treatment modalities.

Figures

Figure 1
Figure 1
Inflammatory response in acute pancreatitis.

References

    1. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology. 2007;132(3):1127–1151.
    1. Sah RP, Saluja A. Molecular mechanisms of pancreatic injury. Current Opinion in Gastroenterology. 2011;27(5):444–451.
    1. Saluja AK, Lerch MM, Phillips PA, Dudeja V. Why does pancreatic overstimulation cause pancreatitis? Annual Review of Physiology. 2007;69:249–269.
    1. Rakonczay Z, Jr., Hegyi P, Takács T, McCarroll J, Saluja AK. The role of NF-κB activation in the pathogenesis of acute pancreatitis. Gut. 2008;57(2):259–267.
    1. Mayerle J, Dummer A, Sendler M, et al. Differential roles of inflammatory cells in pancreatitis. Journal of Gastroenterology and Hepatology. 2012;27(supplement 2):47–51.
    1. Bradley E., III A clinically based classification system for acute pancreatitis: summary of the international symposium on acute pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Archives of Surgery. 1993;128(5):586–590.
    1. Bollen TL, Santvoort H, Besselink MG, et al. The Atlanta classification of acute pancreatitis revisited. British Journal of Surgery. 2008;95(1):6–21.
    1. Dellinger EP, Forsmark CE, Layer P, et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation. Annals of Surgery. 2012;256(6):875–880.
    1. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Medicine. 1996;22(7):707–710.
    1. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48(1):62–69.
    1. Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas. 2001;22(3):274–278.
    1. Mentula P, Kylänpää-Bäck ML, Kemppainen E, et al. Decreased HLA (human leucocyte antigen)-DR expression on peripheral blood monocytes predicts the development of organ failure in patients with acute pancreatitis. Clinical Science. 2003;105(4):409–417.
    1. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Medicine. 2000;26(1, supplement):S124–S128.
    1. Halonen KI, Pettilä V, Leppäniemi AK, Kemppainen EA, Puolakkainen PA, Haapiainen RK. Multiple organ dysfunction associated with severe acute pancreatitis. Critical Care Medicine. 2002;30(6):1274–1279.
    1. McKay CJ, Evans S, Sinclair M, Carter CR, Imrie CW. High early mortality rate from acute pancreatitis in Scotland, 1984–1995. British Journal of Surgery. 1999;86(10):1302–1305.
    1. Buter A, Imrie C, Carter C, Evans S, McKay C. Dynamic nature of early organ dys-function determines outcome in acute pancreatitis. British Journal of Surgery. 2002;89(3):298–302.
    1. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53(9):1340–1344.
    1. Brivet FG, Emilie D, Galanaud P, The Parisian Study Group on Acute Pancreatitis Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Critical Care Medicine. 1999;27(4):749–755.
    1. Nowak A, Marek TA, Nowakowska-Duława E, Rybicka J, Kaczor R. Biliary pancreatitis needs endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy for cure. Endoscopy. 1998;30(9):A256–A259.
    1. Marik PE, Zaloga GP. Meta-analysis of parenteral-nutrition versus enteral nutrition in patients with acute pancreatitis. British Medical Journal. 2004;328(7453):1407–1410.
    1. Petrov MS, van Santvoort HC, Besselink M, van der Heijden G, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: a meta-analysis of randomized trials. Archives of Surgery. 2008;143(11):1111–1117.
    1. O’Reilly DA, Kingsnorth AN. Management of acute pancreatitis: role of antibiotics remains controversial. British Medical Journal. 2004;328(7446):968–969.
    1. Tenner S. Antibiotics in patients with pancreatic necrosis: the controversy continues. American Journal of Gastroenterology. 2007;102(5):p. 1127.
    1. Beger H, Bittner R, Block S, Büchler M. Bacterial contamination of pancreatic necrosis. Gastroenterology. 1986;91(2):433–438.
    1. Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology. 1998;115(6):1513–1517.
    1. Götzinger P, Wamser P, Barlan M, Sautner T, Jakesz R, Függer R. Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality. Shock. 2000;14(3):320–323.
    1. Isenmann R, Rünzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology. 2004;126(4):997–1004.
    1. Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Annals of Surgery. 2007;245(5):674–683.
    1. Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;371(9613):651–659.
    1. Kivisaari L, Somer K, Strandertskjöld-Nordenstam C, et al. Early detection of acute fulminant pancreatitis by contrast-enhanced computed tomography. Scandinavian Journal of Gastroenterology. 1983;18(1):39–41.
    1. de Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut. 1995;37(1):121–126.
    1. Tenner S, Sica G, Hughes M, et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology. 1997;113(3):899–903.
    1. Remes-Troche JM, Uscanga LF, Peláez-Luna M, et al. When should we be concerned about pancreatic necrosis? Analysis from a single institution in Mexico City. World Journal of Surgery. 2006;30(12):2227–2233.
    1. Working Party of the British Society of Gastroenterology; Association of Surgeons of Great Britain and Ireland; Pancreatic Society of Great Britain and Ireland; Association of Upper GI Surgeons of Great Britain and Ireland. UK guidelines for the management of acute pancreatitis. Gut. 2005;54(supplement 3):1–9.
    1. Toouli J, Brooke-Smith M, Bassi C, et al. Guidelines for the management of acute pancreatitis. Journal of Gastroenterology and Hepatology. 2002;17(supplement 1):S15–S39.
    1. Raraty MGT, Halloran CM, Dodd S, et al. Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach. Annals of Surgery. 2010;251(5):787–793.
    1. van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. The New England Journal of Medicine. 2010;362(16):1491–1502.
    1. de Waele JJ, Leppäniemi AK. Intra-abdominal hypertension in acute pancreatitis. World Journal of Surgery. 2009;33(6):1128–1133.
    1. Steer M, Meldolesi J. Pathogenesis of acute pancreatitis. Annual Review of Medicine. 1988;39:95–105.328579
    1. Otani T, Chepilko SM, Grendell JH, Gorelick FS. Codistribution of TAP and the granule membrane protein GRAMP-92 in rat caerulein-induced pancreatitis. American Journal of Physiology. 1998;275(5):G999–G1009.
    1. Singh VP, Saluja AK, Bhagat L, et al. Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. The Journal of Clinical Investigation. 2001;108(9):1387–1395.
    1. Gukovskaya AS, Gukovsky I. Autophagy and pancreatitis. American Journal of Physiology. 2012;303(9):G993–G1003.
    1. Gukovsky I, Pandol SJ, Mareninova OA, Shalbueva N, Jia W, Gukovskaya AS. Impaired autophagy and organellar dysfunction in pancreatitis. Journal of Gastroenterology and Hepatology. 2012;27(supplement 2):27–32.
    1. Grasso D, Ropolo A, Lo Ré A, et al. Zymophagy, a novel selective autophagy pathway mediated by VMP1-USP9x-p62, prevents pancreatic cell death. The Journal of Biological Chemistry. 2011;286(10):8308–8324.
    1. Booth DM, Mukherjee R, Sutton R, Criddle DN. Calcium and reactive oxygen species in acute pancreatitis. Friend or foe? Antioxidants & Redox Signaling. 2011;15(10):2683–2698.
    1. Rau BM, Krüger CM, Schilling MK. Anti-cytokine strategies in acute pancreatitis: pathophysiological insights and clinical implications. Roczniki Akademii Medycznej w Białymstoku. 2005;50:106–115.
    1. Gullo L, Migliori M, Oláh A, et al. Acute pancreatitis in five European countries: etiology and mortality. Pancreas. 2002;24(3):223–227.
    1. Hegyi P, Rakonczay Z., Jr. The role of nitric oxide in the physiology and pathophysiology of the exocrine pancreas. Antioxidants & Redox Signaling. 2011;15:2723–2741.
    1. Escobar J, Pereda J, López-Rodas G, Sastre J. Redox signaling and histone acetylation in acute pancreatitis. Free Radical Biology and Medicine. 2012;52(5):819–837.
    1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644–1655.
    1. Montravers P, Chollet-Martin S, Marmuse JP, Gougerot-Pocidalo MA, Desmonts JM. Lymphatic release of cytokines during acute lung injury complicating severe pancreatitis. American Journal of Respiratory and Critical Care Medicine. 1995;152(5 I):1527–1533.
    1. Malmstrøm ML, Hansen MB, Andersen AM, et al. Cytokines and organ failure in acute pancreatitis: inflammatory response in acute pancreatitis. Pancreas. 2012;41(2):271–277.
    1. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters. 1989;242(2):237–239.
    1. Repo H, Harlan JM. Mechanisms and consequences of phagocyte adhesion to endothelium. Annals of Medicine. 1999;31(3):156–165.
    1. Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. Journal of Hepato-Biliary-Pancreatic Surgery. 2001;8(3):187–194.
    1. Foitzik T, Eibl G, Hotz B, et al. Persistent multiple organ microcirculatory disorders in severe acute pancreatitis. Experimental findings and clinical implications. Digestive Diseases and Sciences. 2002;47(1):130–138.
    1. Lasson A, Ohlsson K. Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thrombosis Research. 1986;41(2):167–183.
    1. Lasson A, Ohlsson K. Disseminated intravascular coagulation and antiprotease activity in acute human pancreatitis. Scandinavian Journal of Gastroenterology. 1986;126:35–39.
    1. Okamura D, Starr ME, Lee EY, Stromberg AJ, Evers BM, Saito H. Age-dependent vulnerability to experimental acute pancreatitis is associated with increased systemic inflammation and thrombosis. Aging Cell. 2012;11(5):760–769.
    1. Lindström O, Kylänpää L, Mentula P, et al. Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Critical Care. 2006;10(1, article R16)
    1. Salomone T, Tosi P, Palareti G, et al. Coagulative disorders in human acute pancreatitis: role for the D-dimer. Pancreas. 2003;26(2):111–116.
    1. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. The Journal of Biological Chemistry. 1994;269(29):18735–18738.
    1. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. American Journal of Physiology. 1997;272(2, part 1):L197–L202.
    1. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. The Journal of Biological Chemistry. 2001;276(14):11199–11203.
    1. Bone R. Sir Isaac Newton, sepsis, SIRS, and CARS. Critical Care Medicine. 1996;24(7):1125–1128.
    1. Mentula P, Kylänpää ML, Kemppainen E, et al. Plasma anti-inflammatory cytokines and monocyte human leucocyte antigen-DR expression in patients with acute pancreatitis. Scandinavian Journal of Gastroenterology. 2004;39(2):178–187.
    1. Mayer JM, Rau B, Siech M, Beger HG. Local and systemic zymogen activation in human acute pancreatitis. Digestion. 2000;62(2-3):164–170.
    1. de Beaux AC, Fearon KCH. Circulating endotoxin, tumour necrosis factor-alpha, and their natural antagonists in the pathophysiology of acute pancreatitis. Scandinavian Journal of Gastroenterology. 1996;31(219):43–46.
    1. Simovic MO, Bonham MJD, Abu-Zidan FM, Windsor JA. Anti-inflammatory cytokine response and clinical outcome in acute pancreatitis. Critical Care Medicine. 1999;27(12):2662–2665.
    1. Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. Gut. 1999;45(6):895–899.
    1. Mentula P, Kylänpää ML, Kemppainen E, et al. Early prediction of organ failure by combined markers in patients with acute pancreatitis. British Journal of Surgery. 2005;92(1):68–75.
    1. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clinical and Experimental Immunology. 1989;77(1):67–70.
    1. Döcke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nature Medicine. 1997;3(6):678–681.
    1. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162–1172.
    1. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. American Journal of Respiratory and Critical Care Medicine. 2002;166(11):1475–1482.
    1. Wolk K, Döcke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood. 2000;96(1):218–223.
    1. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. International Reviews of Immunology. 1998;16(5-6):457–499.
    1. Garcia-Sabrido JL, Valdecantos E, Bastida E, Tellado JM. The anergic state as a predictor of pancreatic sepsis. Zentralblatt für Chirurgie. 1989;114(2):114–120.
    1. Kylänpää-Bäck ML, Takala A, Kemppainen E, et al. Cellular markers of systemic inflammation and immune suppression in patients with organ failure due to severe acute pancreatitis. Scandinavian Journal of Gastroenterology. 2001;36(10):1100–1107.
    1. Richter A, Nebe T, Wendl K, et al. HLA-DR expression in acute pancreatitis. European Journal of Surgery. 1999;165(10):947–951.
    1. Li Q, Wang C, Zhang Q, et al. The role of sphingosine kinase 1 in patients with severe acute pancreatitis. Annals of Surgery. 2012;255(5):954–962.
    1. de Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KCH. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. British Journal of Surgery. 1996;83(3):349–353.
    1. McKay CJ, Gallagher G, Brooks B, Imrie CW, Baxter JN. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. British Journal of Surgery. 1996;83(7):919–923.
    1. Ogawa M. Acute pancreatitis and cytokines: ’second attack’ by septic complication leads to organ failure. Pancreas. 1998;16(3):312–315.
    1. Lundberg AH, Granger DN, Russell J, et al. Quantitative measurement of P- and E-selectin adhesion molecules in acute pancreatitis: correlation with distant organ injury. Annals of Surgery. 2000;231(2):213–222.
    1. Büchler M, Friess H, Uhl W, Beger H. Clinical relevance of experimental acute pancreatitis. European Surgical Research. 1992;24(supplement 1):85–88.
    1. Foitzik T, Hotz HG, Eibl G, Buhr HJ. Experimental models of acute pancreatitis: are they suitable for evaluating therapy? International Journal of Colorectal Disease. 2000;15(3):127–135.
    1. Malleo G, Mazzon E, Siriwardena AK, Cuzzocrea S. TNF-α as a therapeutic target in acute pancreatitis—lessons from experimental models. The Scientific World Journal. 2007;7:431–448.
    1. Grewal H, Mohey el Din A, Gaber L, Kotb M, Gaber A. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. The American Journal of Surgery. 1994;167(1):214–218.
    1. Malleo G, Mazzon E, Genovese T, et al. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-α genetic deletion. Shock. 2007;27(5):542–551.
    1. Guice KS, Oldham KT, Remick DG, Kunkel SL, Ward PA. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis. Journal of Surgical Research. 1991;51(6):495–499.
    1. Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Molecular Biotechnology. 2005;31(3):239–244.
    1. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opinion on Investigational Drugs. 2011;20(11):1555–1564.
    1. Norman J, Franz M, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery. 1995;117(6):648–655.
    1. van Laethem JL, Marchant A, Delvaux A, et al. Interleukin 10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology. 1995;108(6):1917–1922.
    1. Osman MO, Jacobsen NO, Kristensen JU, et al. IT9302, a synthetic interleukin-10 agonist diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery. 1998;124(3):584–592.
    1. Paszkowski AS, Rau B, Mayer JM, Möller P, Beger HG. Therapeutic application of caspase 1/interleukin-1β-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis. Annals of Surgery. 2002;235(1):68–76.
    1. Osman MO, Kristensen JU, Jacobsen NO, et al. A monoclonal anti-interleukin 8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental severe acute necrotising pancreatitis in rabbits. Gut. 1998;43(2):232–239.
    1. Werner J, Z’graggen K, Fernández-del Castillo C, Lewandrowski KB, Compton CC, Warshaw AL. Specific therapy for local and systemic complications of acute pancreatitis with monoclonal antibodies against ICAM-1. Annals of Surgery. 1999;229(6):834–840.
    1. Frossard JL, Saluja A, Bhagat L, et al. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology. 1999;116(3):694–701.
    1. Lundberg AH, Fukatsu K, Gaber L, et al. Blocking pulmonary ICAM-1 expression ameliorates lung injury in established diet-induced pancreatitis. Annals of Surgery. 2001;233(2):213–220.
    1. Foitzik T, Faulhaber J, Hotz HG, Kirchengast M, Buhr HJ. Endothelin receptor blockade improves fluid sequestration, pancreatic capillary blood flow, and survival in severe experimental pancreatitis. Annals of Surgery. 1998;228(5):670–675.
    1. Eibl G, Forgacs B, Hotz HG, Buhr HJ, Foitzik T. Endothelin A but not endothelin B receptor blockade reduces capillary permeability in severe experimental pancreatitis. Pancreas. 2002;25(2):e15–e20.
    1. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. British Journal of Surgery. 1995;82(10):1414–1420.
    1. McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. British Journal of Surgery. 1997;84(9):1239–1243.
    1. Werner J, Hartwig W, Hackert T, et al. Multidrug strategies are effective in the treatment of severe experimental pancreatitis. Surgery. 2012;151(3):372–381.
    1. Uomo G. Lesson from acute experimental pancreatitis: multidrug strategies is effective than single-target therapy. Journal of the Pancreas. 2012;13(5):543–544.
    1. Wilson P, Manji M, Neoptelos J. Acute pancreatitis as a model of sepsis. Journal of Antimicrobial Chemotherapy. 1998;41(supplement 1):51–63.
    1. Fisher CJ, Jr., Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Critical Care Medicine. 2000;28(9):S49–S56.
    1. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000;96(12):3719–3724.
    1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine. 2001;344(10):699–709.
    1. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. The New England Journal of Medicine. 2005;353(13):1332–1341.
    1. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine. 2012;366:2055–2064.
    1. Alsfasser G, Warshaw AL, Thayer SP, et al. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Archives of Surgery. 2006;141(7):670–676.
    1. Babu BI, Genovese T, Mazzon E, et al. Recombinant human activated protein C, (Xigris) attenuated murine cerulein-induced acute pancreatitis via regulation of nuclear factor κB and apoptotic pathways. Pancreas. 2012;41(4):619–628.
    1. Pettilä V, Kylänpää ML, Leppäniemi A, et al. APCAP—activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Critical Care. 2010;14(4, article R139)
    1. Kylänpää ML, Mentula P, Kemppainen E, et al. Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by GM-CSF and IFN-gamma in vitro. Pancreas. 2005;31(1):23–27.
    1. Nierhaus A, Montag B, Timmler N, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Medicine. 2003;29(4):646–651.
    1. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. American Journal of Respiratory and Critical Care Medicine. 2009;180(7):640–648.
    1. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. The American Journal of Surgery. 1998;175(1):76–83.
    1. Messmann H, Vogt W, Holstege A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut. 1997;40(1):80–85.
    1. O’Reilly DA, Roberts JR, Cartmell MT, Demaine AG, Kingsnorth AN. Heat shock factor-1 and nuclear factor-kappaB are systemically activated in human acute pancreatitis. Journal of the Pancreas. 2006;7(2):174–184.
    1. Oiva J, Mustonen H, Kylänpää ML, et al. Patients with acute pancreatitis complicated by organ failure show highly aberrant monocyte signaling profiles assessed by phospho-specific flow cytometry. Critical Care Medicine. 2010;38(8):1702–1708.
    1. Oiva J, Mustonen H, Kylänpää ML, et al. Acute pancreatitis with organ dysfunction associates with abnormal blood lymphocyte signaling: controlled laboratory study. Critical Care. 2010;14(6, article R207)

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner